10x Genomics (TXG): Viking Global opened a new position $67.5M
Viking Global opened a new position in 10x Genomics, per its Q3 2026 13F.
- 747K
- Shares reported
- 0.21%
- Disclosed portfolio weight
- $67.5M
- Reported value
- Holdings as of
- Sep 30, 2026
- Filed
- Nov 16, 2026
What stands out in this filing
- A new position in Q3 2026: 747,087 shares, none in the manager's Q2 2026 filing.
- Reported at $67.5M, 0.21% of the portfolio value in this 13F filing.
- No other tracked manager reported the same kind of change for Q3 2026.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 21, 2026Federal contract · $120K obligatedDepartment of Health and Human Services awarded 10x Genomics, Inc.: $120K obligated to date
- Sep 22, 2026Federal contract · $250K obligatedDepartment of Health and Human Services awarded 10x Genomics, Inc.: $250K obligated to date
- Sep 23, 2026Federal contract · $95K obligatedDepartment of Health and Human Services awarded 10x Genomics, Inc.: $95K obligated to date
- Sep 28, 2026Federal contract · $301K obligatedDepartment of Health and Human Services awarded 10x Genomics, Inc.: $301K obligated to date
- Sep 28, 2026Federal contract · $199K obligatedDepartment of Veterans Affairs awarded 10x Genomics, Inc.: $199K obligated to date
- Oct 7, 20265% stakeARK Investment Management LLC reported a passive stake (13G) of 5.2%
- Oct 28, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 28, 2026, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Ansuman Satpathy and Joseph Gilliam to the Board of Directors as Class III directors effective immediately, each with a term expiring at the Company's 2028 annual meeting of stockholders or until his successor is duly elected and qualified or until…”
- Nov 5, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 10, 2026InsiderCEO sold ~$1.95M of TXG shares in the open market
- Nov 16, 20265% stakeT. Rowe Price Associates, Inc. reported a passive stake (13G) of 14.5%
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for 10x Genomics
For 10x Genomics, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 4 fund holdings reports (13F) and 7 federal contract awards dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TXG page.
How this filing works
Explore the data
Common questions
What does this filing report about 10x Genomics (TXG) stock?
Viking Global opened a new position in 10x Genomics, per its Q3 2026 13F. 747K shares reported, 0.21% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Sep 30, 2026. Filed: Nov 16, 2026.
What stands out in this filing?
A new position in Q3 2026: 747,087 shares, none in the manager's Q2 2026 filing. Reported at $67.5M, 0.21% of the portfolio value in this 13F filing. No other tracked manager reported the same kind of change for Q3 2026.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about 10x Genomics recently?
For 10x Genomics, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 4 fund holdings reports (13F) and 7 federal contract awards dated in the last 90 days. They are listed on the TXG page.
Does this mean TXG stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at 10x Genomics
- SEC Form 144Nov 20, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 13F-HRNov 13, 2026
- SEC Form 4Nov 13, 2026
- USAspending.gov award recordOct 5, 2026
Everything OQRO holds on this company is on its TXG page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
